Vaxcyte (NASDAQ:PCVX) Share Price Breaks Below 50 Day Moving Average on Insider Selling

Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report)’s share price passed below its fifty day moving average during trading on Monday after an insider sold shares in the company. The stock has a fifty day moving average of $62.25 and traded as low as $61.46. Vaxcyte shares last traded at $61.61, with a volume of 707,762 shares traded.

Specifically, insider Harpreet Dhaliwal sold 17,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $67.83, for a total transaction of $1,153,110.00. Following the completion of the transaction, the insider owned 68,085 shares of the company’s stock, valued at $4,618,205.55. This represents a 19.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Upgrades and Downgrades

PCVX has been the subject of several research reports. BTIG Research reaffirmed a “buy” rating and set a $89.00 price target on shares of Vaxcyte in a research note on Monday, October 5th. Guggenheim boosted their price objective on shares of Vaxcyte from $116.00 to $125.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. Bank of America cut their price objective on shares of Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a research report on Monday, September 28th. Wall Street Zen upgraded shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Needham & Company LLC raised their target price on shares of Vaxcyte from $110.00 to $122.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $110.50.

Read Our Latest Research Report on PCVX

Vaxcyte Trading Down 2.8%

The company has a debt-to-equity ratio of 0.04, a current ratio of 4.56 and a quick ratio of 4.56. The business has a 50-day moving average of $62.25 and a 200-day moving average of $57.70. The firm has a market cap of $9.75 billion, a price-to-earnings ratio of -7.64 and a beta of 1.31.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.99) EPS for the quarter, beating the consensus estimate of ($2.11) by $0.12. During the same period last year, the firm earned ($1.56) EPS. Research analysts anticipate that Vaxcyte, Inc. will post -7.51 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. IFP Advisors Inc boosted its holdings in shares of Vaxcyte by 72.8% in the 2nd quarter. IFP Advisors Inc now owns 560 shares of the company’s stock valued at $33,000 after buying an additional 236 shares during the last quarter. Global Retirement Partners LLC increased its holdings in Vaxcyte by 398.7% during the third quarter. Global Retirement Partners LLC now owns 773 shares of the company’s stock worth $44,000 after buying an additional 618 shares during the last quarter. Advisors Asset Management Inc. acquired a new position in Vaxcyte during the third quarter worth $47,000. Manchester Capital Management LLC acquired a new position in Vaxcyte during the third quarter worth $47,000. Finally, Covestor Ltd raised its position in Vaxcyte by 31.1% during the third quarter. Covestor Ltd now owns 939 shares of the company’s stock worth $53,000 after acquiring an additional 223 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Company Profile

(Get Free Report)

Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response. The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.

See Also

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.